Literature DB >> 35342468

Pseudo-hyperthyroidism: Biotin interference in a case with renal failure.

M Demiral1, Z K Kiraz2, I O Alataş2, N Cetin3, B Kirel4.   

Abstract

Introduction: Biotin treatment causes false-low or false-high results in some immunoassays methods. This phenomenon is called as biotin interference. In the present article, a seven-month-old male, with renal failure and laboratory hyperthyroidism due to biotin interference is presented. Case report: High free T4 (fT4), free T3 (fT3), anti-thyroid peroxidase antibody (anti-TPO), anti-thyroglobulin antibody (anti-TG) and low thyroid stimulating hormone (TSH) levels were detected in a seven-month-old male patient who has metabolic acidosis, renal failure, and suspected of metabolic disease. Anti-thyroid drug therapy was started. However, when he was re-evaluated due to the absence of euthyroidism with anti-thyroid therapy (methimazole 0.8 mg/kg /day), it was found that the patient had been given 20 mg/day biotin for acidosis for two months. Biotin interference was considered in hormone measurement. Thyroid function tests were found to be normal 12 days after discontinuation of biotin therapy.
Conclusion: Immunoassay measurements which use biotin should be done 2-7days after the last dose of biotin in patients under biotin treatment, but this time may need be much longer in renal failure patients. During this period or if the biotin therapy cannot be stopped, alternative methods should be preferred for analysis. ©2021 Acta Endocrinologica (Buc).

Entities:  

Keywords:  biotin interference; pseudo-hyperthyroidism; renal failure

Year:  2021        PMID: 35342468      PMCID: PMC8919483          DOI: 10.4183/aeb.2021.319

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  17 in total

1.  Biotin interference on TSH and free thyroid hormone measurement.

Authors:  Jeffrey Sung-Shing Kwok; Iris Hiu-Shuen Chan; Michael Ho-Ming Chan
Journal:  Pathology       Date:  2012-04       Impact factor: 5.306

2.  Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays.

Authors:  Christina Trambas; Zhong Lu; Tina Yen; Ken Sikaris
Journal:  Ann Clin Biochem       Date:  2017-06-29       Impact factor: 2.057

3.  Biotin interference in immunoassays mimicking subclinical Graves' disease and hyperestrogenism: a case series.

Authors:  Marcelo C Batista; Carlos E S Ferreira; Adriana C L Faulhaber; Jairo T Hidal; Simão A Lottenberg; Cristóvão L P Mangueira
Journal:  Clin Chem Lab Med       Date:  2017-05-01       Impact factor: 3.694

4.  [Chronic kidney failure and biotin: A combination inducing unusual results in thyroid and parathyroid investigations, report of 2 cases].

Authors:  Miora Koloina Ranaivosoa; Sébastien Ganel; Arnaud Agin; Sarah Romain; Xavier Parent; Nathalie Reix
Journal:  Nephrol Ther       Date:  2017-11-10       Impact factor: 0.722

5.  Biotin Treatment Mimicking Graves' Disease.

Authors:  Sebastian Kummer; Derik Hermsen; Felix Distelmaier
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

6.  Biochemical Hyperthyroidism in a Newborn Baby Caused by Assay Interaction from Biotin Intake.

Authors:  Inge Bülow Pedersen; Peter Laurberg
Journal:  Eur Thyroid J       Date:  2016-08-12

Review 7.  Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.

Authors:  Laure Peyro Saint Paul; Danièle Debruyne; Delphine Bernard; Donald M Mock; Gilles L Defer
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-02-17       Impact factor: 4.481

8.  Misdiagnosis of Graves' hyperthyroidism due to therapeutic biotin intervention.

Authors:  Yentl De Roeck; Eva Philipse; Theodorus B Twickler; Luc Van Gaal
Journal:  Acta Clin Belg       Date:  2017-11-03       Impact factor: 1.264

9.  High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference.

Authors:  Marie-Liesse Piketty; Dominique Prie; Frederic Sedel; Delphine Bernard; Claude Hercend; Philippe Chanson; Jean-Claude Souberbielle
Journal:  Clin Chem Lab Med       Date:  2017-05-01       Impact factor: 3.694

Review 10.  Best practices in mitigating the risk of biotin interference with laboratory testing.

Authors:  Raffick Bowen; Raul Benavides; Jessica M Colón-Franco; Brooke M Katzman; Alagarraju Muthukumar; Hossein Sadrzadeh; Joely Straseski; Ursula Klause; Nam Tran
Journal:  Clin Biochem       Date:  2019-08-29       Impact factor: 3.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.